Inocras to Offer High Quality and Cost-Effective Whole Genome Sequencing and Bioinformatics Services on Ultima UG 100TM platform
2024年8月15日 - 12:08AM
ビジネスワイヤ(英語)
Inocras Inc., a leader in whole genome sequencing and
bioinformatics, announced today that it is now offering whole
genome sequencing services using the UG 100TM sequencer from Ultima
Genomics, Inc., a developer of a revolutionary new ultra-high
throughput, low cost, next-generation sequencing (NGS)
architecture.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240814284150/en/
Through its CAP accredited and CLIA certified facility in San
Diego, Inocras has offered whole genome sequencing and
bioinformatics services for academic and clinical research
organizations as well as pharmaceutical and biotechnology
companies. With the addition of Ultima’s UG 100, Inocras now
provides more options to customers seeking comprehensive whole
genome sequencing and analytics services.
The UG 100, Ultima’s first commercial product, leverages a
unique sequencing architecture featuring an open silicon wafer
substrate to replace the traditional flow cells as well as a new
sequencing chemistry that reduces overall sequencing costs.
“Having completed exhaustive feasibility tests, we are ready to
offer whole genome sequencing and bioinformatics services on
Ultima’s UG 100 system.” said Jehee Suh, CEO of Inocras Inc. “This
enables us to meet diverse needs of our customers in the genomics
community with price flexibility. We announced collaboration with
Ultima in 2023 with a shared vision to make whole genome insights
affordable. That future is already here today.”
“Inocras’s whole genome sequencing and bioinformatics
capabilities showcase the power of Ultima’s ultra-high throughput,
low-cost sequencing technologies,” said Gilad Almogy, Founder and
CEO of Ultima Genomics. “We are very excited to see our shared
vision of affordable genomic solutions coming to fruition.”
About Inocras, Inc:
Inocras Inc. (formerly Genome Insight, Inc) is a pioneering
provider of whole genome sequencing and analytics for cancer and
rare diseases. The company is dedicated to unlocking the full
potential of whole genomic data to enable precision health for
everyone. For researchers, it provides customizable research
solutions including whole genome sequencing, bioinformatics, and
expert advisory services. For clinicians and patients, it offers
CancerVision, a cancer profiling tumor-normal paired whole genome
test, and RareVision, a rare disease diagnosis whole genome test.
It operates a CLIA certified and CAP accredited lab in San Diego.
For more information about Inocras, please visit Inocras.com.
About Ultima Genomics, Inc.
Ultima Genomics is unleashing the power of genomics at scale.
The Company's mission is to continuously drive the scale of genomic
information to enable unprecedented advances in biology and
improvements in human health. With humanity on the cusp of a
biological revolution, there is a virtually endless need for more
genomic information to address biology's complexity and dynamic
change—and a further need to challenge conventional next-generation
sequencing technologies. Ultima's revolutionary new sequencing
architecture drives down the costs of sequencing to help overcome
the tradeoffs that scientists and clinicians are forced to make
between the breadth, depth and frequency with which they use
genomic information. The new sequencing architecture was designed
to scale far beyond conventional sequencing technologies, lower the
cost of genomic information and catalyze the next phase of genomics
in the 21st century. To learn more, visit
www.ultimagenomics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240814284150/en/
Inocras Sohee Cho Global Marketing Manager media@inocras.com